We are working to further define the Wnt1/b-catenin-driven molecular mechanisms that inhibit chemokine production by cDCs, hoping to reveal novel insights into the complex regulation of cross-priming and open new avenues for optimizing cancer immunotherapies. This evidence concerns the gene WNT1 and cancer.